Sagimet Biosciences Inc. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Sagimet Biosciences Inc. (SGMT) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 9.32 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-11
- Sagimet Biosciences Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-06-30 was 9.32M shares, a 36.23% increase year-over-year.
- Sagimet Biosciences Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 7.57M shares, a 14.82% increase year-over-year.
- Sagimet Biosciences Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-09-30 was 6.51M shares, a 26.01% increase year-over-year.
- Sagimet Biosciences Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-06-30 was 6.84M shares, a 22.31% increase year-over-year.
- Sagimet Biosciences Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 6.55M shares, a 23.47% increase from fiscal 2024.
- Sagimet Biosciences Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 5.31M shares, a 8.61% increase from fiscal 2023.
- Sagimet Biosciences Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 4.89M shares, a 75.50% decline from fiscal 2022.
- Sagimet Biosciences Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 19.95M shares.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month |
|---|---|---|---|---|
| 2026-06-30 | 9.32M shares 10-Q · filed 2026-08-11 | 9.32M shares 10-Q · filed 2026-08-11 | ||
| 2026-03-31 | 7.57M shares 10-Q · filed 2026-05-12 | |||
| 2025-12-31 | 6.55M shares 10-K · filed 2026-03-11 | |||
| 2025-09-30 | 6.51M shares 10-Q · filed 2025-11-13 | 6.51M shares 10-Q · filed 2025-11-13 | ||
| 2025-06-30 | 6.84M shares 10-Q · filed 2026-08-11 | 6.84M shares 10-Q · filed 2026-08-11 | ||
| 2025-03-31 | 6.59M shares 10-Q · filed 2026-05-12 | |||
| 2024-12-31 | 5.31M shares 10-K · filed 2026-03-11 | |||
| 2024-09-30 | 5.17M shares 10-Q · filed 2025-11-13 | 5.17M shares 10-Q · filed 2025-11-13 | ||
| 2024-06-30 | 5.59M shares 10-Q · filed 2025-08-13 | 5.59M shares 10-Q · filed 2025-08-13 | ||
| 2024-03-31 | 4.65M shares 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | 4.89M shares 10-K · filed 2025-03-12 | |||
| 2023-09-30 | 3.77M shares 10-Q · filed 2024-11-14 | 3.77M shares 10-Q · filed 2024-11-14 | ||
| 2023-06-30 | 20.51M shares 10-Q · filed 2024-08-14 | 20.51M shares 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | 19.95M shares 10-Q · filed 2024-05-15 | |||
| 2022-12-31 | 19.95M shares 10-K · filed 2024-03-25 | |||
| 2022-09-30 | 18.96M shares 10-Q · filed 2023-11-13 | 18.96M shares 10-Q · filed 2023-11-13 | ||
| 2022-06-30 | 18.92M shares 10-Q · filed 2023-08-21 | 18.92M shares 10-Q · filed 2023-08-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |